Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GERALD A MAGUIRE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1144300302
CMS profile
324491
Location
SAN JUAN CAPISTRACO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$71,589.39

98 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $27,399.85 33
Teva Pharmaceuticals USA, Inc. $12,513.99 7
Otsuka America Pharmaceutical, Inc. $11,999.29 25
ACADIA Pharmaceuticals Inc $9,811.36 13
Neurocrine Biosciences, Inc. $5,708.00 6
Sunovion Pharmaceuticals Inc. $2,656.90 12
Eisai Inc. $1,000.00 1
ITI, Inc. $500.00 1

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GERALD A MAGUIRE

NPI 1144300302 · CMS profile ID 324491

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

SAN JUAN CAPISTRACO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144300302?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GERALD A MAGUIRE, NPI 1144300302, CMS profile ID 324491. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144300302?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). GERALD A MAGUIRE, NPI 1144300302, CMS profile ID 324491. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144300302?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
GERALD A MAGUIRE, NPI 1144300302, CMS profile ID 324491, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1144300302?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

98 matching records · $71,589.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 98 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–98 of 98.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $559.1403/05/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152319 CMS
Janssen Pharmaceuticals, Inc $995.0403/05/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152321 CMS
Janssen Pharmaceuticals, Inc $123.8703/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152353 CMS
Otsuka America Pharmaceutical, Inc. $2,246.0003/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749287 CMS
Janssen Pharmaceuticals, Inc $124.7103/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152347 CMS
Sunovion Pharmaceuticals Inc. $28.4702/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398249 CMS
Sunovion Pharmaceuticals Inc. $34.8102/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398251 CMS
Sunovion Pharmaceuticals Inc. $38.0402/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398253 CMS
Sunovion Pharmaceuticals Inc. $40.0002/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398255 CMS
Sunovion Pharmaceuticals Inc. $41.4202/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398257 CMS
Sunovion Pharmaceuticals Inc. $243.1102/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398261 CMS
Sunovion Pharmaceuticals Inc. $10.7202/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398245 CMS
Sunovion Pharmaceuticals Inc. $25.4102/28/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398247 CMS
Sunovion Pharmaceuticals Inc. $127.7002/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398259 CMS
Sunovion Pharmaceuticals Inc. $325.1302/28/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398263 CMS
Sunovion Pharmaceuticals Inc. $717.0902/28/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748398265 CMS
Otsuka America Pharmaceutical, Inc. $15.2302/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749283 CMS
Janssen Pharmaceuticals, Inc $2,100.0002/26/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152337 CMS
Janssen Pharmaceuticals, Inc $53.1302/26/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152339 CMS
Janssen Pharmaceuticals, Inc $78.1702/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152341 CMS
Otsuka America Pharmaceutical, Inc. $22.0102/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749259 CMS
Otsuka America Pharmaceutical, Inc. $39.4802/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749263 CMS
Otsuka America Pharmaceutical, Inc. $638.7902/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749267 CMS
Otsuka America Pharmaceutical, Inc. $263.9402/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749271 CMS
Otsuka America Pharmaceutical, Inc. $44.8402/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749275 CMS
Otsuka America Pharmaceutical, Inc. $13.7502/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749279 CMS
Otsuka America Pharmaceutical, Inc. $71.0802/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748749255 CMS
Janssen Pharmaceuticals, Inc $111.6402/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152335 CMS
Teva Pharmaceuticals USA, Inc. $3,438.0002/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749521609 CMS
Teva Pharmaceuticals USA, Inc. $4,375.0002/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749521611 CMS
Teva Pharmaceuticals USA, Inc. $4,375.0002/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749521615 CMS
Janssen Pharmaceuticals, Inc $900.0002/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719152307 CMS
Teva Pharmaceuticals USA, Inc. $123.7401/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749521619 CMS
ACADIA Pharmaceuticals Inc $35.0001/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569247 CMS
ACADIA Pharmaceuticals Inc $8.9501/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569253 CMS
ACADIA Pharmaceuticals Inc $19.2301/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569257 CMS
ACADIA Pharmaceuticals Inc $235.5401/23/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569263 CMS
ACADIA Pharmaceuticals Inc $2,500.0001/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569267 CMS
ACADIA Pharmaceuticals Inc $5.9501/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569207 CMS
ACADIA Pharmaceuticals Inc $125.0001/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569213 CMS
ACADIA Pharmaceuticals Inc $235.5401/22/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569218 CMS
ACADIA Pharmaceuticals Inc $6,500.0001/22/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569221 CMS
ACADIA Pharmaceuticals Inc $7.9501/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569227 CMS
ACADIA Pharmaceuticals Inc $24.9501/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569231 CMS
ACADIA Pharmaceuticals Inc $50.0001/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569237 CMS
ACADIA Pharmaceuticals Inc $63.2501/22/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748569241 CMS
Teva Pharmaceuticals USA, Inc. $17.2501/20/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749521613 CMS
Teva Pharmaceuticals USA, Inc. $125.2001/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749521621 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $216,555.97 279
PY2020 $71,589.39 98
PY2021 $21,189.49 25
PY2022 $145,311.13 174
PY2023 $389,607.59 421
PY2024 $492,013.29 503
PY2025 $493,391.30 466

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,082,353.85 102
PY2024 Principal investigator $1,868,924.72 52
PY2023 Principal investigator $1,138,106.57 70
PY2022 Principal investigator $73,327.97 40
PY2021 Principal investigator $8,835.70 2
PY2020 Principal investigator $15,820.40 6
PY2019 Principal investigator $585,625.04 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

102 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,500.00 12/19/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine No dispute reported 06/30/2026 1235998068
Principal investigator 1 Janssen Research & Development, LLC $58.00 12/19/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357681
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,202.71 11/21/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine No dispute reported 06/30/2026 1235998066
Principal investigator 1 Janssen Research & Development, LLC $20.00 11/17/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357643
Principal investigator 1 ABBVIE INC. $4,844.53 11/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202523793
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $238.11 11/10/2025 Non-covered Recipient Entity
CALNEURO RESEARCH GROUP
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365923
Principal investigator 1 ABBVIE INC. $803.50 11/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202523603
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,950.00 11/03/2025 Non-covered Recipient Entity
CALNEURO RESEARCH GROUP
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365067
Principal investigator 1 Janssen Research & Development, LLC $304.77 10/27/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357515
Principal investigator 1 Janssen Research & Development, LLC $4,375.00 10/27/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357595
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $202.00 10/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220802222
Principal investigator 1 Janssen Research & Development, LLC $185.00 09/29/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357551
Principal investigator 1 Janssen Research & Development, LLC $10,281.00 09/29/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357648
Principal investigator 1 ABBVIE INC. $2,500.00 09/25/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202512448
Principal investigator 1 Janssen Research & Development, LLC $248.83 09/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357572
Principal investigator 1 Janssen Research & Development, LLC $14,204.00 09/15/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357664
Principal investigator 1 ABBVIE INC. $650.00 09/04/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202510116
Principal investigator 1 Janssen Research & Development, LLC $487.00 08/25/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357565
Principal investigator 1 Janssen Research & Development, LLC $487.00 08/25/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357610
Principal investigator 1 Janssen Research & Development, LLC $106.85 08/18/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357633
Principal investigator 1 Janssen Research & Development, LLC $4,793.00 08/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357617
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,331.53 07/30/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049851
Principal investigator 1 Janssen Research & Development, LLC $112.86 07/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357530
Principal investigator 1 Janssen Research & Development, LLC $176.00 07/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357537
Principal investigator 1 Janssen Research & Development, LLC $4,793.00 07/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357603
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,144.85 07/14/2025 Non-covered Recipient Entity
Citrials
An open label, single arm, extension trial to examine long-termsafety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X) No dispute reported 06/30/2026 1220802230
Principal investigator 1 ABBVIE INC. $52,974.50 07/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202493859
Principal investigator 1 ABBVIE INC. $1,600.00 07/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202493861
Principal investigator 1 ABBVIE INC. $1,500.00 07/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202493863
Principal investigator 1 ABBVIE INC. $81,560.65 07/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202493865
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689682
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689684
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 07/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689686
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 07/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689688
Principal investigator 1 ABBVIE INC. $17,611.00 06/27/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202493607
Principal investigator 1 Janssen Research & Development, LLC $56.92 06/09/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357672
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,049.79 06/05/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242350080
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689674
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689676
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689678
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689680
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $185,000.00 05/16/2025 Non-covered Recipient Entity
Cenexel Cit
An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants with DSM-5 Schizophrenia No dispute reported 06/30/2026 1235998300
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $855.77 05/13/2025 Non-covered Recipient Entity
Citrials
An open label, single arm, extension trial to examine long-termsafety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X) No dispute reported 06/30/2026 1220802226
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 05/13/2025 Non-covered Recipient Entity
Citrials
An open label, single arm, extension trial to examine long-termsafety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X) No dispute reported 06/30/2026 1220802228
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 05/05/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175357625
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689666
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689668
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689670
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689672
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $102.45 04/29/2025 Non-covered Recipient Entity
Citrials
An open label, single arm, extension trial to examine long-termsafety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X) No dispute reported 06/30/2026 1220802224
Principal investigator 1 Janssen Research & Development, LLC $9,586.00 04/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357581
Principal investigator 1 Janssen Research & Development, LLC $12,381.00 04/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357688
Principal investigator 1 Janssen Research & Development, LLC $69.91 04/18/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175357656
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $656.20 04/16/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220802220
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $73.82 04/15/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220802218
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 04/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357544
Principal investigator 1 Janssen Research & Development, LLC $718.00 04/03/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175357702
Principal investigator 1 ABBVIE INC. $2,880.00 04/02/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202468539
Principal investigator 1 ABBVIE INC. $200.00 04/02/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202468547
Principal investigator 1 ABBVIE INC. $437.62 04/02/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202468599
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689658
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689660
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689662
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689664
Principal investigator 1 Janssen Research & Development, LLC $3,658.00 03/24/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175357557
Principal investigator 1 ABBVIE INC. $3,248.19 03/19/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464780
Principal investigator 1 ABBVIE INC. $570.50 03/19/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464783
Principal investigator 1 ABBVIE INC. $2,822.92 03/19/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464787
Principal investigator 1 ABBVIE INC. $3,284.42 03/19/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464814
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,508.38 03/17/2025 Non-covered Recipient Entity
Citrials
Connex-2 No dispute reported 06/30/2026 1220802244
Principal investigator 1 Janssen Research & Development, LLC $3,658.00 03/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175357696
Principal investigator 1 Janssen Research & Development, LLC $14,000.00 03/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175357523
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689646
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689648
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689650
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689652
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,407.00 03/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220802216
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 02/25/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689654
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 02/14/2025 Non-covered Recipient Entity
Citrials
Connex-2 No dispute reported 06/30/2026 1220802232
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $268.53 02/14/2025 Non-covered Recipient Entity
Citrials
Connex-2 No dispute reported 06/30/2026 1220802234
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 02/14/2025 Non-covered Recipient Entity
Citrials
Connex-2 No dispute reported 06/30/2026 1220802236
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $459.04 02/14/2025 Non-covered Recipient Entity
Citrials
Connex-2 No dispute reported 06/30/2026 1220802238
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $895.05 02/14/2025 Non-covered Recipient Entity
Citrials
Connex-2 No dispute reported 06/30/2026 1220802240
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $573.00 02/14/2025 Non-covered Recipient Entity
Citrials
Connex-2 No dispute reported 06/30/2026 1220802242
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 02/03/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175357589
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689634
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689636
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689638
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689640
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689642
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689644
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $75.00 01/29/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242329865
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,710.15 01/29/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242329867
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,354.00 01/23/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220802214
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $233,763.77 01/17/2025 Non-covered Recipient Entity
Cenexel Cit
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1235998298
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $93,251.26 01/16/2025 Non-covered Recipient Entity
Clinical Innovations Inc
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1235998086
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $210,714.19 01/03/2025 Non-covered Recipient Entity
Cenexel Cit
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235998296
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689626
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689628
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689630
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689632
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Citrials
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220689656